International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)
Predicts overall and progression-free survival in DLBCL based on risk factors.
INSTRUCTIONS
Note: IPI results are included for historical comparisons only. Use in CD20+ DLBCL patients. Do not use in patients with HIV, secondary malignancies, low grade lymphoproliferative disorders, or comorbidities precluding curative therapy attempt.
Result:
Please fill out required fields.
Dr. Laurie H. Sehn
About the creator
Laurie H. Sehn, MD, is a medical oncologist at the British Columbia Cancer Agency and a clinical associate professor at the University of British Columbia. She is on the Board of Directors and is the director of research fellowships for the Lymphoma Foundation Canada (LFC). Dr. Sehn is an active researcher studying aspects of lymphoid cancers.
To view Dr. Laurie H. Sehn's publications, visit PubMed
Are you Dr. Laurie H. Sehn? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.
Content Contributors
- Randall Pierce, MD